公开(公告)号：US10814018B2

公开(公告)日：2020-10-27

申请号：US13881585

申请日：2011-10-25

Applicant: Moshe Gomori ,  Hyla Allouche-Arnon ,  Rachel Katz-Brull

Inventor： Moshe Gomori ,  Hyla Allouche-Arnon ,  Rachel Katz-Brull

IPC: A61K49/10 ,  C07B59/00 ,  C07H3/08

Abstract: The present invention provides isotopically labeled deoxy-glucose and derivatives thereof, methods of their preparation, ration, kits comprising them and uses thereof for spin hyperpolarized magnetic resonance imaging, utilized in the quantitative and qualitative diagnosis of states, conditions, diseases, or disorders in the body of a subject.

公开(公告)号：US10736973B2

公开(公告)日：2020-08-11

申请号：US15129255

申请日：2015-03-26

Applicant: TECHNOLOGY INNOVATION MOMENTUM FUND (ISRAEL) LIMITED PARTNERSHIP

Inventor： Gil Navon ,  Michal Rivlin ,  Ilan Tsarfaty

IPC: A61K49/10

Abstract: Provided are methods and formulations for imaging at least one body region of a subject, employing a glucose analog resistant or inactive to phosphrylation, or which is not a substrate for hexokinase.

公开(公告)号：US20200246490A1

公开(公告)日：2020-08-06

申请号：US16652892

申请日：2018-10-05

Applicant: YALE UNIVERSITY

Inventor： Gerald I. Shulman ,  Rachel Jamison Perry ,  Gary Cline ,  Douglas Rothman ,  Kitt Petersen

IPC: A61K49/10 ,  A61K49/00 ,  G01N33/58 ,  G01N33/66 ,  A61K9/00

Abstract: The present provides a Positional Isotopomer NMR Tracer Analysis (PINTA) method that can be used to noninvasively assess rates of hepatic mitochondrial oxidation (VCS) and/or pyruvate carboxylase (VPC) flux in a subject. In certain embodiments, the methods utilize a combined NMR/gas chromatography-mass spectrometry analysis of plasma following infusion of [3-13C]lactate and glucose tracer. The method of the invention provides investigators with a tool to non-invasively examine the role of altered hepatic mitochondrial metabolism and study the effects of therapeutic interventions for the treatment of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and type 2 diabetes (T2D).

公开(公告)号：US20200237935A1

公开(公告)日：2020-07-30

申请号：US16851585

申请日：2020-04-17

Applicant: Wisconsin Alumni Research Foundation

Inventor： Jamey Weichert ,  Reinier Hernandez ,  Ray Zhang ,  Anatoly Pinchuk

IPC: A61K51/04 ,  A61K9/00 ,  A61B5/055 ,  C07B59/00 ,  A61K49/00 ,  C07F9/6524 ,  A61K49/10 ,  A61K49/08

Abstract: Dual-modality contrast agents are disclosed herein, having the general formula: R1 includes a chelating moiety that is chelated to a Mn2+ isotope. The disclosed contrast agents differentially target a wide range of malignant tumor tissues, and can be simultaneously used as contrast agents for both magnetic resonance imaging (MRI) and positron emission topography (PET) imaging. Accordingly, the disclosed contrast agent can be used in diagnosing and monitoring solid tumor cancers.

公开(公告)号：US10718778B2

公开(公告)日：2020-07-21

申请号：US15313445

申请日：2015-05-29

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Brent R. Martin ,  Christopher Baker Tom

IPC: A61K49/00 ,  G01N33/68 ,  C12P21/00 ,  A61K49/10

Abstract: The present invention relates to methods for detecting sulfenylation within thiol groups in proteins, metabolites, or materials. Protein sulfenylation (Cys-SOH) describes the reversible post-translational modification of protein thiols by hydrogen peroxide, and plays a central role in oxidative signaling (see, e.g., Paulsen, C. E. & Carroll, K. S. 2013 Chemical Reviews 113, 4633-679). Growth factor stimulation activates NADPH oxidase enzymes, releasing a local burst of hydrogen peroxide, which transiently oxidizes the nuclcophilic cysteine of protein phosphatases and other proximal redox active thiols (see, e.g., Paulsen, C. E. et al., 2012 Nature Chemical Biology 8, 57-64). In addition to masking functional cysteine's, sulfenylation is also a critical intermediate towards irreversible cysteine oxidation.

公开(公告)号：US10663548B2

公开(公告)日：2020-05-26

申请号：US15166711

申请日：2016-05-27

Applicant: The University of Western Ontario

Inventor： Jamu Alford ,  Blaine Chronik ,  Timothy Scholl

IPC: G01R33/56 ,  A61K49/10 ,  G01R33/44 ,  G01R33/561 ,  G01R33/381 ,  G01R33/385 ,  G01R33/50 ,  G10K9/00

Abstract: A method for contrast agent enhanced magnetic resonance imaging (MRI) of a target sample, comprising generating a magnetic field shift in a polarizing magnetic field during a relaxation portion of an MRI pulse sequence and thereafter acquiring an MR image.

公开(公告)号：US20200155712A1

公开(公告)日：2020-05-21

申请号：US16752307

申请日：2020-01-24

Applicant: GE HEALTHCARE AS

Inventor： Mikkel Jacob THANING ,  Andreas Richard MEIJER

IPC: A61K49/10 ,  A61K31/28 ,  A61K9/00 ,  C07D257/00

Abstract: The present invention relates to a method of removal of metal ion impurities, such as calcium, from lanthanide metal complexes of macrocyclic chelators. The method uses a scavenger resin to remove metal ions, displaced from chelator, by an excess of lanthanide ions. Also provided is a method of preparation of MRI contrast agents, from the purified lanthanide metal complex, by the addition of a defined excess chelator.

公开(公告)号：US10653713B2

公开(公告)日：2020-05-19

申请号：US13267243

申请日：2011-10-06

Applicant: Deepak Ramesh Thakker ,  Lisa L. Shafer ,  Greg Stewart

Inventor： Deepak Ramesh Thakker ,  Lisa L. Shafer ,  Greg Stewart

IPC: A61K9/00 ,  A61K31/711 ,  A61K49/10 ,  A61K49/14 ,  A61M5/168 ,  A61M5/142

Abstract: Broad cerebrospinal fluid (CSF) distribution of an agent is achievable by delivering the agent in a liquid formulation to the CSF at flow rates less than 500 microliters per hour, such as between about 2 microliters per hour and about 100 microliters per hour.

公开(公告)号：US10576169B2

公开(公告)日：2020-03-03

申请号：US15531431

申请日：2015-11-27

Applicant: GE HEALTHCARE AS

Inventor： Mikkel Jacob Thaning ,  Andreas Richard Meijer

IPC: A61K49/10 ,  C07D257/00 ,  A61K9/00 ,  A61K31/28

Abstract: The present invention relates to a method of removal of metal ion impurities, such as calcium, from lanthanide metal complexes of macrocyclic chelators. The method uses a scavenger resin to remove metal ions, displaced from chelator, by an excess of lanthanide ions. Also provided is a method of preparation of MRI contrast agents, from the purified lanthanide metal complex, by the addition of a defined excess chelator.

公开(公告)号：US20200046861A1

公开(公告)日：2020-02-13

申请号：US16543880

申请日：2019-08-19

Applicant: Board of Regents of The University of Nebraska

Inventor： Janina Baranowska-Kortylewicz ,  Zbigniew P. Kortylewicz

IPC: A61K51/04 ,  A61K49/10 ,  A61K31/7072 ,  A61K47/54

Abstract: Methods of using butyrylcholinesterase targeted, and optionally androgen receptor targeted radiolabeled compounds, e.g., cycloSalingenyl pyrimidine nucleoside monophosphates, for targeted delivery of cytotoxic and/or imaging compounds to cancer cells.